Welcome to our dedicated page for AlloVir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on AlloVir stock.
AlloVir, Inc. (NASDAQ: ALVR) is a leading entity in the clinical-stage biotech sector, focusing on allogeneic T cell immunotherapy for viral diseases affecting immunocompromised patients. The company is dedicated to the research, development, and commercialization of innovative T-cell therapies designed to restore natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.
AlloVir is known for its proprietary technology platforms that produce off-the-shelf, multi-virus-specific T cells. These cells are used to address the urgent medical needs of patients suffering from viral-associated diseases. The company’s lead product candidate, posoleucel, has been in clinical trials for the prevention and treatment of infections caused by six common and devastating viruses, including adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), and JC virus (JCV).
Despite the promise of posoleucel, AlloVir recently announced the discontinuation of its three global Phase 3 studies due to futility analyses that showed the studies were unlikely to meet their primary endpoints. However, the studies did not identify any safety concerns, maintaining the potential for further exploration of posoleucel in other contexts.
AlloVir’s pipeline also includes ALVR106, targeted at respiratory infections like respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and parainfluenza virus (PIV), now completing Phase 1b/2a clinical trials. Additionally, ALVR107 aims to address chronic hepatitis B with preclinical studies supporting its potential efficacy.
Founded in 2013 and based in Waltham, Massachusetts, AlloVir continues to evaluate strategic options for its future, including mergers, sales, divestitures, or licensing opportunities. With substantial capital in reserves, AlloVir is positioned to explore and advance its mission to treat and prevent viral diseases.
For more detailed information, visit AlloVir's website or follow the company on LinkedIn and Twitter.
AlloVir has initiated a Phase 3 study of posoleucel, an allogeneic T-cell therapy for preventing viral infections in high-risk hematopoietic cell transplant patients. Preliminary Phase 2 data presented at the EBMT Annual Meeting show that 21 of 24 patients remained free of significant infections through Week 14. Posoleucel targets six life-threatening viruses, with a potential market of 40,000 patients annually. The study will enroll approximately 300 patients, assessing safety and efficacy through a 14-week interval.
AlloVir (NASDAQ: ALVR) announced that CEO Diana Brainard will engage in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. The live webcast will be accessible on AlloVir's Investors & Press section, with a replay available for 30 days post-event.
AlloVir focuses on allogeneic T cell immunotherapy, aiming to restore immunity against viral diseases in patients with weakened immune systems. The company is advancing several mid- and late-stage clinical trials and utilizes innovative technology for treating multiple viral infections.
AlloVir (ALVR) reported its 2021 financial results, revealing a net loss of
AlloVir has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lead product, posoleucel, aimed at treating adenovirus (AdV) infections post-allogeneic hematopoietic stem cell transplant. This follows positive results from the Phase 2 CHARMS study. The company has also initiated a Phase 3 registrational study for posoleucel and is enrolling patients. Additionally, a Phase 1/2 trial for ALVR106, targeting respiratory viral infections, is also underway.
AlloVir (NASDAQ: ALVR), a clinical-stage allogeneic T-cell immunotherapy company, announced that CEO Diana Brainard will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. An audio-only webcast will be available on the AlloVir website, with an archived replay accessible for 30 days post-presentation. AlloVir develops innovative therapies to combat life-threatening viral diseases in patients with weakened immune systems, utilizing single- and multi-virus-specific T cells in its clinical trials.
AlloVir (Nasdaq: ALVR) announced the departure of Chief Medical Officer Dr. Augustin Melian at year-end 2023. Dr. Melian joined the company in March 2019 and significantly advanced the clinical development of its lead product, posoleucel. He will assist in transitioning to ensure continuity. Richard Riese, SVP of Clinical Research, will oversee ongoing clinical programs, including the Phase 3 studies for posoleucel. AlloVir focuses on innovative cell therapies targeting life-threatening viral diseases for patients with weakened immune systems.
AlloVir has announced preliminary data from a Phase 2 study of posoleucel for preventing viral infections in high-risk allogeneic hematopoietic cell transplant patients. Out of 23 patients, only three clinically significant infections occurred, and no end-organ viral disease was reported. With 11 of 13 patients free from significant infections through Week 14, the data supports advancing posoleucel into a Phase 3 trial, expected to begin in 1H 2022. The findings highlight the potential for posoleucel to transform treatment for vulnerable patient populations.
AlloVir (NASDAQ: ALVR) will host a virtual investor event on December 13, 2021, at 8:00 a.m. EST, providing a corporate update and initial data from its Phase 2 study of posoleucel for multi-virus prevention. This investigational therapy targets six life-threatening viruses in allo-HSCT recipients. Key speakers include CEO Diana Brainard and Dr. Sanjeet Dadwal, who will discuss the risks of viral infections. A live webcast will be available on the AlloVir website, with an archived replay for 30 days.
AlloVir, Inc. (Nasdaq: ALVR), a clinical-stage cell therapy company, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from November 22 to December 2, 2021, accessible on the conference website and AlloVir's Investor section at ir.allovir.com. AlloVir focuses on restoring immunity against viral diseases, utilizing innovative allogeneic T cell therapies to treat patients with weakened immune systems. For more details, visit www.allovir.com.
AlloVir (ALVR) reported its Q3 2021 financial results, highlighting advancements in its virus-specific T cell (VST) therapy programs. The company is set to present positive interim data on posoleucel at the ASH Annual Meeting. The ongoing Phase 2 study is aimed at preventing significant viral infections in high-risk allo-HSCT patients. Financially, net loss increased to $45.5 million, or $0.72 per share, with total cash and securities at $275.8 million. R&D expenses rose to $33.1 million, reflecting expanded activities in product development and staffing.
FAQ
What is the current stock price of AlloVir (ALVR)?
What is the market cap of AlloVir (ALVR)?
What is AlloVir, Inc.?
What does AlloVir's lead product candidate, posoleucel, target?
Why were the Phase 3 trials for posoleucel discontinued?
What other products are in AlloVir’s pipeline?
What are AlloVir's future plans?
Where is AlloVir based?
How can I follow AlloVir’s updates?
Who is the CEO of AlloVir, Inc.?
When was AlloVir founded?
What was the financial status of AlloVir as of September 2023?
